FY2030 Earnings Forecast for MIRM Issued By HC Wainwright

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research note issued to investors on Monday, January 26th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of $6.16 for the year. HC Wainwright currently has a “Buy” rating and a $130.00 target price on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. During the same period in the previous year, the firm earned ($0.30) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 47.1% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the stock. Raymond James Financial restated a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Citizens Jmp raised their target price on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research report on Friday, December 19th. Morgan Stanley upped their price target on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. Finally, Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $104.92.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $99.27 on Tuesday. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $99.44. The firm has a 50-day moving average of $78.36 and a two-hundred day moving average of $71.54. The firm has a market capitalization of $5.10 billion, a PE ratio of -115.43 and a beta of 0.48. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. CWM LLC boosted its position in Mirum Pharmaceuticals by 30.8% during the third quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares during the period. Legal & General Group Plc lifted its stake in shares of Mirum Pharmaceuticals by 0.4% in the second quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock worth $2,189,000 after buying an additional 176 shares during the last quarter. MCF Advisors LLC boosted its holdings in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares during the period. Teacher Retirement System of Texas grew its stake in Mirum Pharmaceuticals by 2.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after buying an additional 215 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its stake in Mirum Pharmaceuticals by 34.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock valued at $70,000 after buying an additional 243 shares during the last quarter.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, insider Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $90.27, for a total value of $623,855.97. Following the completion of the sale, the insider owned 11,305 shares of the company’s stock, valued at approximately $1,020,502.35. The trade was a 37.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Eric Bjerkholt sold 1,421 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $132,621.93. Following the completion of the sale, the chief financial officer owned 42,127 shares of the company’s stock, valued at $3,931,712.91. This represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 32,429 shares of company stock worth $3,039,396 in the last ninety days. Company insiders own 22.87% of the company’s stock.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron purchased 131,425 shares at $68.48 (≈$9.0M), increasing his stake by ~40%, a strong insider vote of confidence in the company and its valuation. Director Form 4
• Positive Sentiment: HC Wainwright upgraded MIRM to Buy, raised the price target from $102 to $130 and published an aggressive FY2030 EPS projection ($6.16), signaling bullish long‑term expectations from a coverage analyst and supporting higher share valuations. HC Wainwright Coverage
• Positive Sentiment: Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare-disease pipeline and global footprint—an acquisition likely viewed as strategically accretive and supportive of future revenue growth. Acquisition Announcement
• Positive Sentiment: Coverage and market reaction have pushed MIRM to a new 52‑week high following the analyst upgrade, which can attract momentum/technical buyers. 52‑Week High Article
• Negative Sentiment: CEO Christopher Peetz sold 6,831 shares at ~$96.19 (~$657K), reducing his stake by ~3.9%. CEO Form 4
• Negative Sentiment: Other senior exec sales the same day: COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares) and SVP Jolanda Howe (842 shares) — these reduce insider holdings and may concern some investors about near‑term insider liquidity. COO Form 4 CFO Form 4 SVP Form 4

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.